---
title: "Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer: Safety questions"
description: "Safety questions on Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Monitoring. Questions: What are KEYTRUDA side effects with chemotherapy in early-stage TNBC (KEYNOTE-522)? How are KEYTRUDA immune-mediated side effects managed? How does KEYTRUDA cause immune-mediated side effects? Can KEYTRUDA cause liver problems (immune-mediated hepatitis)? 1 further question follow. 5 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/safety"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer: Safety questions

Manufacturer: Merck Sharp & Dohme LLC  
Prescribing information: [Keytruda](https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf)

## Safety

<a id="keytruda-trial-safety"></a>

### What are KEYTRUDA side effects with chemotherapy in early-stage TNBC (KEYNOTE-522)?

> “In KEYNOTE-522, when KEYTRUDA was administered with neoadjuvant chemotherapy (carboplatin and paclitaxel followed by doxorubicin or epirubicin and cyclophosphamide) followed by surgery and continued adjuvant treatment with KEYTRUDA as a single agent (n=778) to patients with newly diagnosed, previously untreated, high-risk early-stage TNBC, fatal adverse reactions occurred in 0.9% of patients, including 1 each of adrenal crisis, autoimmune encephalitis, hepatitis, pneumonia, pneumonitis, pulmonary embolism, and sepsis in association with multiple organ dysfunction syndrome and myocardial infarction. Serious adverse reactions occurred in 44% of patients receiving KEYTRUDA; those ≥2% were febrile neutropenia (15%), pyrexia (3.7%), anemia (2.6%), and neutropenia (2.2%). KEYTRUDA was discontinued in 20% of patients due to adverse reactions. The most common reactions (≥1%) resulting in permanent discontinuation were increased ALT (2.7%), increased AST (1.5%), and rash (1%). The most common adverse reactions (≥20%) in patients receiving KEYTRUDA with chemotherapy followed by KEYTRUDA alone were fatigue (70%), nausea (67%), alopecia (61%), rash (52%), constipation (42%), diarrhea and peripheral neuropathy (41% each), stomatitis (34%), vomiting (31%), headache (30%), arthralgia (29%), pyrexia (28%), cough (26%), abdominal pain (24%), decreased appetite (23%), insomnia (21%), and myalgia (20%).”

Source: [KEYTRUDA: KEYNOTE-522 - Adverse Reactions & Safety Data, captured 2026-11-08](https://www.keytrudahcp.com/safety/adverse-reactions/early-stage-triple-negative-breast-cancer/#:~:text=In%20KEYNOTE%2D522%2C%20when%20KEYTRUDA%20was,insomnia%20%2821%25%29%2C%20and%20myalgia%20%2820%25%29.)

<a id="keytruda-immune-mediated-reactions"></a>

### How are KEYTRUDA immune-mediated side effects managed?

> “Withhold or permanently discontinue KEYTRUDA and KEYTRUDA QLEX depending on severity of the immune-mediated adverse reaction. In general, if KEYTRUDA and KEYTRUDA QLEX require interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose adverse reactions are not controlled with corticosteroid therapy.”

Source: [KEYTRUDA: KEYNOTE-522 - Adverse Reactions & Safety Data, captured 2026-11-08](https://www.keytrudahcp.com/safety/adverse-reactions/early-stage-triple-negative-breast-cancer/#:~:text=Withhold%20or%20permanently%20discontinue%20KEYTRUDA,not%20controlled%20with%20corticosteroid%20therapy.)

<a id="keytruda-immune-mediated-mechanism"></a>

### How does KEYTRUDA cause immune-mediated side effects?

> “KEYTRUDA and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection 165 mg + 2,000 units/mL are monoclonal antibodies that belong to a class of drugs that bind to either the programmed death receptor-1 (PD-1) or the programmed death ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, can affect more than one body system simultaneously, and can occur at any time after starting treatment or after discontinuation of treatment. Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.”

Source: [KEYTRUDA: KEYNOTE-522 - Adverse Reactions & Safety Data, captured 2026-11-08](https://www.keytrudahcp.com/safety/adverse-reactions/early-stage-triple-negative-breast-cancer/#:~:text=Immune%2DMediated%20Adverse%20Reactions-,KEYTRUDA%20and%20KEYTRUDA%20QLEX%E2%84%A2%20%28pembrolizumab%20and%20berahyaluronidase%20alfa%2Dpmph%29%20Injection%20165,and%20fatal%20immune%2Dmediated%20adverse%20reactions.)

<a id="keytruda-hepatitis"></a>

### Can KEYTRUDA cause liver problems (immune-mediated hepatitis)?

> “KEYTRUDA and KEYTRUDA QLEX can cause immune-mediated hepatitis. Immune-mediated hepatitis occurred in 0.7% (19/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.4%), and Grade 2 (0.1%) reactions. Systemic corticosteroids were required in 68% (13/19) of patients; additional immunosuppressant therapy was required in 11% of patients. Hepatitis led to permanent discontinuation of KEYTRUDA in 0.2% (6) and withholding in 0.3% (9) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, none had recurrence. Hepatitis resolved in 79% of the 19 patients.”

Source: [KEYTRUDA: KEYNOTE-522 - Adverse Reactions & Safety Data, captured 2026-11-08](https://www.keytrudahcp.com/safety/adverse-reactions/early-stage-triple-negative-breast-cancer/#:~:text=KEYTRUDA%20and%20KEYTRUDA%20QLEX%20can%20cause%20immune%2Dmediated%20hepatitis.,79%25%20of%20the%2019%20patients.)

## Monitoring

<a id="keytruda-tnbc-cortisol-monitoring"></a>

### What lab monitoring does KEYTRUDA require in early-stage TNBC?

> “Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. For patients with triple-negative breast cancer (TNBC) treated with KEYTRUDA or KEYTRUDA QLEX in the neoadjuvant setting, monitor blood cortisol at baseline, prior to surgery, and as clinically indicated.”

Source: [KEYTRUDA: KEYNOTE-522 - Adverse Reactions & Safety Data, captured 2026-11-08](https://www.keytrudahcp.com/safety/adverse-reactions/early-stage-triple-negative-breast-cancer/#:~:text=Evaluate%20liver%20enzymes%2C%20creatinine%2C%20and,surgery%2C%20and%20as%20clinically%20indicated.)

## Related pages
- [Medical information: Keytruda (pembrolizumab): High-risk early-stage triple-negative breast cancer](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/guidelines)
